J Endocrinol Metab
Journal of Endocrinology and Metabolism, ISSN 1923-2861 print, 1923-287X online, Open Access
Article copyright, the authors; Journal compilation copyright, J Endocrinol Metab and Elmer Press Inc
Journal website http://www.jofem.org

Original Article

Volume 9, Number 4, August 2019, pages 90-94

Dapagliflozin Add-On Therapy Improves Body Composition and Metabolic Parameters in Overweight Type 2 Diabetic Patients: A Pilot Study

Ugo Di Folcoa, b, Alessandra Gattia, Maria Rosaria Nardonea, Claudio Tubilia

aUOSD Diabetology, “S. Camillo-Forlanini” Hospital, Rome, Italy
bCorresponding Author: Ugo Di Folco, UOSD Diabetology, “S. Camillo-Forlanini” Hospital, Rome, Italy

Manuscript submitted April 9, 2019, accepted August 1, 2019
Short title: Dapagliflozin Add-On Therapy in T2DM Patients
doi: https://doi.org/10.14740/jem564


Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2-i) inhibit renal glucose reabsorption in the proximal tubules, and reduce plasma glucose, body weight and cardiovascular risk in patients with type 2 diabetes mellitus (T2DM). The data on the effect of SGLT-2i on body composition are conflicting: in some reports, they reduce fat mass, while in other reports, they determine reduction of extra- and intra-cellular fluids. The aim of our pilot study was to investigate the body compartments changes and the effects on glycemia and plasma lipids of add-on SGLT2-i dapagliflozin therapy in poorly controlled overweight/obese T2DM patients.

Methods: Fifty-six overweight (body mass index (BMI) > 25) uncontrolled (HbA1c > 53 mmol/mol; 7%) T2DM outpatients were recruited. They were treated with metformin and basal insulin (group A) or metformin (group B). Weight, BMI, waist circumference (WC), fasting blood glucose (FPG), HbA1c, plasma lipids, bioelectric parameters and derived body compartments (phase angle (pA), total body water (TBW), fat free mass (FFM) and fat mass (FM)) were assessed at baseline (T0) and after 16 weeks (T1) of dapagliflozin 10 mg add-on treatment. Student’s t-test and one-way analysis of variance (ANOVA) were used to compare the T0 and T1 data.

Results: After 16 weeks, all the patients had weight loss (-3.0 ± 0.6 kg, P < 0.0001) and reduced WC (-2.5 ± 0.6 cm, P < 0.0001). Weight reduction was significant in both groups separately (group A: -2.5 ± 0.3 kg, P ≤ 0.001; group B: -3.4 ± 0.4 kg, P ≤ 0.001) and was higher in group B. FFM was not impaired in group A (from 60.2 ± 5.2 to 59.5 ± 8.1 kg; ns) and in group B (from 60.4 ± 6.2 to 59.3 ± 6.6 kg; ns). FM decreased in all the patients (29.9 ± 6.84 kg vs. 26.30 ± 7.4 kg, P < 0.000); a higher reduction was found in group B (-3.6 ± 1.2 kg, P < 0.001) vs. group A (-2.3 ± 1.3 kg, P < 0.001). Metabolic control improved in all the patients: FPG 172 ± 49.4 mg/dL vs. 137 ± 36.8 mg/dL at T1, P < 0.0001; HbA1c 69 ± 9.3 mmol/mol (8.5±1.5%) vs. 60 ± 8.7 mmol/mol (7.6±1.4%), P = 0.000. In group A, insulin dose was reduced by 9.3%. Cholesterol and triglycerides (TG) levels decreased in overall population (181.8 ± 48.8 mg/dL vs. 170.7 ± 40.7, P = 0.003; 172 ± 93 mg/dL vs. 143.2 ± 87.8, P = 0.000).

Conclusions: Dapagliflozin add-on therapy induced weight loss and metabolic improvement in overweight and obese T2DM patients. Also insulin-treated patients had weight loss (2.5 kg). Bioelectric impedance analysis (BIA) demonstrated FM loss without FFM impairment and was confirmed to be a simple and effective method to assess body composition in clinical practice.

Keywords: Dapagliflozin; Type 2 diabetes mellitus; Obesity; Body composition; Bioelectric impedance analysis


Traditional antidiabetic oral agents (such as sulphonylureas) and insulin induce weight gain in type 2 diabetes mellitus (T2DM) patients [1], impairing insulin sensitivity over the time.

An optimal therapeutic approach to T2DM includes drugs not only effective to get HbA1c targets without inducing hypoglycemia and weight gain, but also capable to reduce cardiovascular risk. Different classes of drugs with original mechanism of action such as sodium-glucose cotransporter-2 inhibitors (SGLT2-i) have been recently introduced. They selectively inhibit glucose reabsorption in the proximal tubules of the kidney, increasing renal excretion and reducing plasma glucose levels. Thus, they promote a negative energy balance leading to body weight loss [2]. Recent studies have demonstrated an improvement in cardiovascular risk profile of T2DM patients with SGLT-2i, such as canagliflozin [3], empagliflozin [4] and dapagliflozin [5, 6]. Few studies at present have evaluated the SGLT-2i-induced weight loss features in terms of body composition changes, and available data are conflicting [7, 8]. Middle long-term observations show body fat reduction: in a 2-year study with dual energy X-rays absorptiometry (DEXA) on T2DM subjects, the association of dapagliflozin to metformin reduced body weight, and this was principally due to fat mass (FM) reduction [9]; other studies in T2DM subjects reported reduction of liver and subcutaneous FM with computed tomography (CT) scan [10, 11].

On the other hand, the short-term weight loss is primarily due to extra-cellular water (ECW) and to intra-cellular water (ICW) secondly; a report on T2DM subjects treated with tofogliflozin and evaluated with bioelectric impedance put in evidence a rearrangement of body fluids compartments, so that the authors concluded a recommendation to monitor kidney function in the first phases of SGLT2-i treatment [12].

The aim of our pilot study was to investigate the effect on weight and body composition (assessed by bioelectrical impedance analysis (BIA)) of SGLT2-i agent dapagliflozin 10 mg once a day as add-on treatment in overweight/obese T2DM subjects with poor metabolic control. We focused our interest to explore whether the eventual weight loss induced by the therapy was related to body fat mass rather than lean mass decrease or fluid unbalance. BIA is an inexpensive, reproducible, not invasive and sufficiently accurate method to assess body composition in clinical practice [13]. Secondly, we investigated the effects of this therapy on glucose control and plasma lipid profile and the eventual correlation with weight and body fat changes.

Materials and Methods▴Top 

Fifty-six overweight T2DM outpatients were recruited at the Diabetes Clinic of our hospital.

Inclusion criteria were body mass index (BMI) > 25 kg/m2 and inadequate glycemic control (HbA1c > 53 mmol/mol; 7%). Acetylsalicylic acid (ASA) and other antiplatelets agents, statins and antihypertensive drugs use were reported. The current therapies were not changed. Exclusion criteria were: renal impairment (estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2), age > 75 years, diuretic therapy, chronic and/or recurrent urinary tract infections and acute illness. Subjects suffering from cancer and diseases affecting nutritional status and body composition (e.g. inflammatory bowel diseases and liver cirrhosis) were also excluded. We divided subjects into two groups: one under metformin and basal insulin (group A, n = 25) and the other under metformin treatment alone (group B, n = 31).

BIA was conducted with a BIA 101 Akern® single frequency (50 kHz) analyzer (Florence); body compartments were calculated according to manufacturer equation.

Weight, BMI, waist circumference (WC), fasting blood glucose (FPG), HbA1c, lipid profile, hematocrit (Hct), eGFR calculated with MDRD formula, albumin excretion rate (AER), blood urea nitrogen (BUN), bioelectrical parameters and body composition derived compartments (phase angle (pA), total body water (TBW), fat free mass (FFM) and FM) were assessed at baseline (T0) and after 16 weeks (T1) of dapagliflozin 10 mg add-on treatment. This second-/third-line option was planned according to the Italian Standard of Care for Diabetes; all the patients underwent a retraining about lifestyle change intervention. A moderate low calorie diet (20 kcal/kg daily; total carbohydrate (CHO) 40%; fat 30%; protein 1.0 - 1.2 g/kcal daily) was prescribed [14].

The number of the visits and the contacts with the team of care was the same of the routine outpatient follow-up.

This study was conducted in compliance with the ethical standards of the responsible institution on human subjects as well as with the Helsinki Declaration and informed consent was provided by participants. All the patients were informed about the research purpose and procedure, benefits and risks, having the freedom to drop out from the study at any time. The study protocol was approved by the Ethical Committee of the San Camillo-Forlanini Hospital in Rome.

The data were reported as average ± standard deviation. Statistical analysis was performed using unpaired Student’s t-test to compare the two treatment groups, while one-way analysis of variance (ANOVA) was used to compare the T0 and T1 data.


The age of the overall population was 56 ± 10 years, BMI was 31.2 ± 4.5 kg/m2, HbA1c was 69 ± 6.2 mmol/mol (8.5±1%) and diabetes duration was 16 ± 2 years. Twenty-five patients (group A) were treated with metformin (maximum tolerated dose) plus basal insulin (mean dose 0.64 UI/kg/day), and 31 patients (group B) were treated with metformin alone (maximum tolerated dose). The two groups were comparable for age, diabetes duration, weight, BMI, WC, HbA1c, plasma lipids and body composition at T0. Owing to upgrade of the pharmacological treatment for the poor metabolic control, dapagliflozin (10 mg/day) was added. Table 1 shows the clinical characteristics, anthropometric, and bioelectric and biochemical measurements at T0. T1 data after 16 weeks are presented in Table 2. All the patients presented significant weight loss (-3.0 ± 0.6 kg, P < 0.0001) and WC reduction (-2.5 ± 0.6 cm, P < 0.0001). Weight loss was also significant in both single groups (group A: -2.5 ± 0.3 kg, P ≤ 0.001; group B: -3.4 ± 0.4 kg, P ≤ 0.001), higher in group B. BIA showed that pA, TBW, ICW and FFM did not change at T1 compared to baseline in both groups: FFM decreased slightly in group A from 60.2 ± 5.2 to 59.5 ± 8.1 kg (ns) and in group B from 60.4 ± 6.2 to 59.3 ± 6.6 kg (ns). On the contrary, FM significantly decreased in all the patients (baseline: 29.9 ± 6.84 kg vs. T2: 26.30 ± 7.4 kg, P < 0.000); a higher reduction was found in group B (-3.6 ± 1.2 kg, P < 0.001) vs. insulin-treated group A (-2.3 ± 1.3 kg, P < 0.001).

Table 1.
Click to view
Table 1. Baseline Characteristics of Two Groups

Table 2.
Click to view
Table 2. Anthropometric, Biochemical and Bioelectrical Measures of the Two Groups at T0 and T1 After 16 Treatment Weeks

Metabolic control improved in all the patients: FPG 172 ± 49.4 mg/dL vs. 137 ± 36.8 mg/dL of T1, P < 0.0001; HbA1c 69 ± 9.3 mmol/mol (8.5±1.5%) vs. 60 ± 8.7 mmol/mol (7.6±1.4 %) of T1, P = 0.000. In group A, insulin dose was reduced by 9.3%. Total cholesterol (TC) and triglycerides (TG) levels significantly decreased in overall population (181.8 ± 48.8 mg/dL vs. T1: 170.7 ± 40.7, P = 0.003; 172 ± 93 mg/dL vs. T1: 143.2 ± 87.8, P = 0.000). Finally, there was no significant side effect related to fluid loss: Hct, eGFR, AER and BUN did not change in both groups at T1 compared to baseline; no severe hypoglycaemic event was reported by the patients and no other adverse events were recorded (urinary infections, ketoacidosis and hypotension).


Randomized trials [3, 4, 6] and a real-world study [5] demonstrated a reduction of cardiovascular risk in T2DM during SGLT2-i therapy; in all these studies, weight loss was reported. Obesity is an independent cardiovascular risk factor and is related to all causes mortality [15] and weight loss is related to cardiovascular morbidity and mortality reduction [16]. Our pilot study confirms the favorable dapagliflozin add-on therapy effects on weight reduction and metabolic control improvement in a population of overweight and obese T2DM patients. These effects have been observed for both treatment groups (A: metformin + basal insulin, B: metformin alone). The anabolic effect of insulin and its conflicting role on weight loss are well known; however, patients in group A, despite the lower weight change, have shown benefits in metabolic control and reduced insulin dose. Group A lost 2.5 kg after 16 weeks; this reduction is higher than that reported in a 2-year study on 193 T2DM patients treated with dapagliflozin and insulin vs. placebo and insulin group (1.5 kg at 16 weeks stable at the end of the study) [17].

Metabolic improvement after dapagliflozin introduction is significant, including FPG, HbA1c, TG and cholesterol reduction. It is likely that this result could also be related to weight and visceral fat reduction. We aimed to investigate the body composition changes during dapagliflozin treatment.

Some studies [10, 11] have recently reported a reduction of total FM without affecting skeletal muscle mass or a reduction in liver and abdominal subcutaneous fat assessed by CT scan in T2DM patients. CT is a gold standard method to study body composition and distribution, but it is not feasible in routine settings. Bioelectric analysis is a fast, simple, inexpensive, not invasive and reproducible method, suitable in clinical practice. This method allows calculating body water distribution in intra- and extra-cellular compartments and estimate FFM [18]. Predictive population specific equations are crucial to estimate body compartments. FM is estimated indirectly and the error rate is about 5% everyway. Even if in our study the estimated FM loss is significant, we must underline that the most significant result is the FFM preservation. These results seem to exclude ECW or ICW loss, as previously reported [12].

Furthermore, our data on body composition suggest a specific FM reduction, without hemodynamic and kidney function impairment, and a favorable effect on the metabolic profile.

Recently, it was demonstrated that body fat percentage in bioelectrical measurements is independently associated with the risk of future cardiovascular events and that the calculated percentage with the validated predictive equations can be a more predictive measurement in cardiovascular risk assessment than BMI or WC [19]. Our pilot study provides additional evidence about these results using a BIA. It is a short-term real-world observation and its limitations are the small size of the sample and the lack of a placebo-controlled arm. Furthermore, studies on different groups of patients, in association with other antidiabetic drugs and for longer time, are needed to confirm and better understand the relationship between weight and FM loss and reduction of cardiovascular risk in T2DM.


None to declare.

Financial Disclosure

Investigators did not receive funding for this work.

Conflict of Interest

The authors have no potential conflict of interest to disclose for this article.

Informed Consent

The authors give informed consent.

Author Contributions

UDF researched data, made statistical analysis and reviewed manuscript. AG wrote the manuscript. MRN edited the manuscript. CT designed the study, reviewed the manuscript and is the guarantor of the work.

  1. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837-853.
  2. Nauck MA, Del Prato S, Duran-Garcia S, Rohwedder K, Langkilde AM, Sugg J, Parikh SJ. Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add-on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin. Diabetes Obes Metab. 2014;16(11):1111-1120.
    doi pubmed
  3. Neal B, Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Stein P, Desai M, et al. Rationale, design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS) - a randomized placebo-controlled trial. Am Heart J. 2013;166(2):217-223 e211.
    doi pubmed
  4. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
    doi pubmed
  5. Kosiborod M, Lam CSP, Kohsaka S, Kim DJ, Karasik A, Shaw J, Tangri N, et al. Cardiovascular events associated with SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL 2 study. J Am Coll Cardiol. 2018;71(23):2628-2639.
    doi pubmed
  6. Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Silverman MG, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347-357.
    doi pubmed
  7. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, Sugg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97(3):1020-1031.
    doi pubmed
  8. Fadini GP, Bonora BM, Zatti G, Vitturi N, Iori E, Marescotti MC, Albiero M, et al. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017;16(1):42.
    doi pubmed
  9. Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, Sjostrom CD, Sugg J, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab. 2014;16(2):159-169.
    doi pubmed
  10. Kurinami N, Sugiyama S, Yoshida A, Hieshima K, Miyamoto F, Kajiwara K, Jinnouch K, et al. Dapagliflozin significantly reduced liver fat accumulation associated with a decrease in abdominal subcutaneous fat in patients with inadequately controlled type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;142:254-263.
    doi pubmed
  11. Sugiyama S, Jinnouchi H, Kurinami N, Hieshima K, Yoshida A, Jinnouchi K, Nishimura H, et al. Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes. J Atheroscler Thromb. 2018;25(6):467-476.
    doi pubmed
  12. Hirose S, Nakajima S, Iwahashi Y, Seo A, Takahashi T, Tamori Y. Impact of the 8-week administration of tofogliflozin for glycemic control and body composition in Japanese patients with type 2 diabetes mellitus. Intern Med. 2016;55(22):3239-3245.
    doi pubmed
  13. Sinha J, Duffull SB, Al-Sallami HS. A Review of the Methods and Associated Mathematical Models Used in the Measurement of Fat-Free Mass. Clin Pharmacokinet. 2018;57(7):781-795.
    doi pubmed
  14. Standard Italiani per la Cura del Diabete Mellito, AMD SID. 2018.
  15. Sun YQ, Burgess S, Staley JR, Wood AM, Bell S, Kaptoge SK, Guo Q, et al. Body mass index and all cause mortality in HUNT and UK Biobank studies: linear and non-linear mendelian randomisation analyses. BMJ. 2019;364:l1042.
    doi pubmed
  16. Pimenta GP, Saruwatari RT, Correa MR, Genaro PL, Aguilar-Nascimento JE. Mortality, weight loss and quality of life of patients with morbid obesity: evaluation of the surgical and medical treatment after 2 years. Arq Gastroenterol. 2010;47(3):263-269.
    doi pubmed
  17. Wilding JP, Woo V, Rohwedder K, Sugg J, Parikh S, Dapagliflozin 006 Study G. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years. Diabetes Obes Metab. 2014;16(2):124-136.
    doi pubmed
  18. Lukaski HC, Kyle UG, Kondrup J. Assessment of adult malnutrition and prognosis with bioelectrical impedance analysis: phase angle and impedance ratio. Curr Opin Clin Nutr Metab Care. 2017;20(5):330-339.
    doi pubmed
  19. Byambasukh O, Eisenga MF, Gansevoort RT, Bakker SJ, Corpeleijn E. Body fat estimates from bioelectrical impedance equations in cardiovascular risk assessment: The PREVEND cohort study. Eur J Prev Cardiol. 2019;26(9):905-916.
    doi pubmed

This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Journal of Endocrinology and Metabolism is published by Elmer Press Inc.


Browse  Journals  


Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics


World Journal of Oncology

Gastroenterology Research

Journal of Hematology


Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity


Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research


Journal of Neurology Research

International Journal of Clinical Pediatrics



Journal of Endocrinology and Metabolism, bimonthly, ISSN 1923-2861 (print), 1923-287X (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)

This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.jofem.org   editorial contact: editor@jofem.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.

Disclaimer: The views and opinions expressed in the published articles are those of the authors and do not necessarily reflect the views or opinions of the editors and Elmer Press Inc. This website is provided for medical research and informational purposes only and does not constitute any medical advice or professional services. The information provided in this journal should not be used for diagnosis and treatment, those seeking medical advice should always consult with a licensed physician.